| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/13/2006 | WO2006072202A1 A rantes-dt390 recombinant immunotoxin plasmid targeting activated th1 cells and production method and uses thereof |
| 07/13/2006 | WO2006072166A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 07/13/2006 | WO2006057902A3 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses |
| 07/13/2006 | WO2006057901A3 2-METHYLENE-19-NOR-1α-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES |
| 07/13/2006 | WO2006032879A3 Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| 07/13/2006 | WO2006021457A3 Pyrimidine derivatives |
| 07/13/2006 | WO2006020889A3 Dendritic cell vaccines for treating cancer made from embryonic stem cells |
| 07/13/2006 | WO2006016353A3 Elastase inhibitor in leukemia |
| 07/13/2006 | WO2006006954A3 Modified fusion peptides derived from a p53 domain against malignant and/or transformed mammalian cells |
| 07/13/2006 | WO2006004833A3 Pyrrolotriazine kinase inhibitors |
| 07/13/2006 | WO2006002088A3 Amino-quinazoline derivatives as antitumor agents |
| 07/13/2006 | US20060154985 For therapy of prostate cancer |
| 07/13/2006 | US20060154982 for treatment of insulin-like growth factor-1 receptor (IGF-1R) dependent diseases such as cancer, psoriasis, arteriosclerosis or is at risk of restenosis of the coronary arteries after vascular surgery |
| 07/13/2006 | US20060154977 Therapeutic molecules and methods-1 |
| 07/13/2006 | US20060154976 Reducing the incidence of fibrosis by the co-administration of effective amounts of telmisartan and ramipril; strokes; cardiovascular disorders; organoprotective, tissue-protective, and vasculoprotective effects of combined treatment |
| 07/13/2006 | US20060154969 Adenosine receptor selective modulators |
| 07/13/2006 | US20060154966 Novel raloxifene acid additon salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these |
| 07/13/2006 | US20060154944 N-(3,5-dimethylphenyl)-1-(3-fluorophenyl)-1,9-dihydrospiro[ beta-carboline-4,1'-cyclopropane]-2(3H)-carboxamide;affinity for mitochondrial benzodiazepine receptors preventive/therapeutic to stress-related diseases; irritable bowel syndrome; anxiolytic agents; nervous/respiratory system disorders;asthma |
| 07/13/2006 | US20060154933 Inhibitors of Cdc25 phosphatases |
| 07/13/2006 | US20060154920 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij] quinoline derivatives as antipsychotic and antiobesity agents |
| 07/13/2006 | US20060154893 Exopolysaccharides delivery system for active molecules |
| 07/13/2006 | US20060154868 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 07/13/2006 | US20060154854 Molecules for targeting and releasing therapeutic compounds, and the use thereof |
| 07/13/2006 | US20060153884 can be associated with the peptide 111-136 of HARP; cancer treatment |
| 07/13/2006 | US20060153883 HM1.24-utilizing cancer vaccines |
| 07/13/2006 | US20060153863 Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's |
| 07/13/2006 | US20060153862 Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses |
| 07/13/2006 | US20060153859 Ganglioside-KLH conjugate vaccine with QS-21 |
| 07/13/2006 | US20060153858 Drug delivery of a liquid comprising an antigen such as tumor-associated antigen directly to an area of high lymphatic drainage or a lymphatic system of the mammal to induce an antigen-specific Cytotoxic T lymphocyte (CTL) response; sustained release |
| 07/13/2006 | US20060153853 Cancers of the breast, prostate, colorectal, lung, thyroid, ovaries, and brain as well as in childhood leukaemias, glioblastomas, and neuroblastomas; Insulin-like Growth Factor Binding Protein (IGFBP) with reduced IGF (Insulin-like Growth Factor) release characteristics |
| 07/13/2006 | US20060153850 Antibodies to M-CSF |
| 07/13/2006 | US20060153848 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| 07/13/2006 | US20060153841 Nucleotide sequence which hybridizes to the complement of the specific nucleic acid molecule over its full length under conditions of incubation and encodes a polypeptide which costimulates T cell proliferation in vitro |
| 07/13/2006 | US20060153837 Treating autoimmune diseases with humanized anti-CD401 antibodies |
| 07/13/2006 | US20060153836 Using monoclonal antibody specific for kidney injury-molecule-1 (KIM-1) to diagnose, prevent and treat cell proliferative and kidney disorders; immunotherapeutics |
| 07/13/2006 | US20060153825 Use of protein histidine phosphatase |
| 07/13/2006 | US20060153770 Method of treating tumors |
| 07/13/2006 | US20060151899 Process for producing drug ultramicroparticle and apparatus therefor |
| 07/13/2006 | DE102004063347A1 Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate Ready gemcitabine and Gemcitabinlösungskonzentrate |
| 07/13/2006 | DE102004063269A1 New 9,10-dihydroxy-1,4-dihydroanthracene-1,4-dione compound is protein kinase D inhibitor useful for tumor suppression, inhibition of tumor angiogenesis and the treatment of cancers |
| 07/13/2006 | DE10013539B4 Lipopolysaccharide aus Escherichia coli, Verfahren zu deren Herstellung und deren Verwendungen Lipopolysaccharides from Escherichia coli, to processes for their preparation and their uses |
| 07/13/2006 | CA2594143A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 07/13/2006 | CA2593693A1 Framework residue substituted humanized col-1 antibodies and their use |
| 07/13/2006 | CA2593648A1 Targeted chimeric molecules for cancer therapy |
| 07/13/2006 | CA2593212A1 Cripto binding molecules |
| 07/13/2006 | CA2593005A1 Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof |
| 07/13/2006 | CA2592743A1 Disubstituted ureas as kinase inhibitors |
| 07/13/2006 | CA2591991A1 Triazolophthalazines |
| 07/13/2006 | CA2591138A1 Antibodies against antigen presenting cells and uses thereof |
| 07/13/2006 | CA2590110A1 Kinase modulators and method of use |
| 07/13/2006 | CA2589893A1 Inhibitors of checkpoint kinases |
| 07/13/2006 | CA2589830A1 Ubiquitin ligase inhibitors |
| 07/13/2006 | CA2564296A1 Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| 07/12/2006 | EP1679371A1 Method of evaluating cancerization degree |
| 07/12/2006 | EP1679370A1 Method of evaluating cancerization degree |
| 07/12/2006 | EP1679320A1 Derivatives of breast cancer antigen her-2 for therapeutical use |
| 07/12/2006 | EP1679073A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(imino-heterocyclyl)-phenyl-amide derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 07/12/2006 | EP1679064A2 Pharmaceutical compositions containing rapamycin derivatives |
| 07/12/2006 | EP1678302A1 Antisense oligonucleotides for prevention of metastasis formation of cancer cells |
| 07/12/2006 | EP1678207A1 Regulation of matrix metalloproteinases by psp94 family members |
| 07/12/2006 | EP1678197A2 Methods and compositions for pdgf-c activation and inhibition |
| 07/12/2006 | EP1678194A1 The moduilation of hyaluronan synthesis and degradation in the treatment of disease |
| 07/12/2006 | EP1678193A1 Hepatocellular carcinoma specific promoter and uses thereof |
| 07/12/2006 | EP1678189A2 Process for the preparation of trans- or cis-diammoniumdichlorodihydroxyplatinum(iv) salts and derivatives and their use for the preparation of pharmaceutical active agents |
| 07/12/2006 | EP1678170A1 Use of a compound of formula (i) as an inhibitor of aromatase for therapeutic purposes and compounds of formula (1) thereas |
| 07/12/2006 | EP1678163A1 Novel imidazole derivatives and their use as pharmaceutical agents |
| 07/12/2006 | EP1678133A1 Sequence selective pyrrole and imidazole polyamide metallocomplexes |
| 07/12/2006 | EP1678121A2 Tao kinase modulators and methods of use |
| 07/12/2006 | EP1677875A1 A protein involved in ovarian cancer |
| 07/12/2006 | EP1677811A1 Medicament on the basis of honey, preparation and use thereof |
| 07/12/2006 | EP1677805A2 Pancreatic cancer treatment |
| 07/12/2006 | EP1677803A2 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
| 07/12/2006 | EP1677794A2 Methods of treating disorder |
| 07/12/2006 | EP1677739A2 Methods of identifying agents that inhibit the growth of cancer cells |
| 07/12/2006 | EP1496865B1 Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulations |
| 07/12/2006 | EP1441718B1 Use of carbinols for the treatment of neuropathic dysfunction |
| 07/12/2006 | EP1427730B1 Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| 07/12/2006 | EP1392311B1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 07/12/2006 | EP1335923B1 Condensed pyridoindole derivatives |
| 07/12/2006 | EP1325748B1 Cyanidin mixture for the treatment of large intestine cancer |
| 07/12/2006 | EP1289557B1 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
| 07/12/2006 | EP1124950B1 Morpholino based p53 antisense oligonucleotide, and uses thereof |
| 07/12/2006 | EP1121439B1 Methods and compositions for inhibiting neoplastic cell growth |
| 07/12/2006 | EP1121157B1 A novel component in the hedgehog signalling pathway |
| 07/12/2006 | EP1071764B1 Antisense oligonucleotides for the inhibition of integrin alphav-subunit expression |
| 07/12/2006 | EP1012178B1 Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerases |
| 07/12/2006 | EP0869808B1 Use of glu-trp dipeptides for the manufacture of a medicament for the treatment of different conditions involving neovascularization |
| 07/12/2006 | EP0756488B1 Detection of alterations of tumor suppressor genes for the diagnosis of cancer |
| 07/12/2006 | CN1802387A Cancerous disease modifying antibodies |
| 07/12/2006 | CN1802361A M-stage kinesin inhibitor |
| 07/12/2006 | CN1802357A Aminopyrimidine derivatives and their medical use |
| 07/12/2006 | CN1802163A An extract of faeces bombycis and the preparation method thereof, use and device for diagnosing or treating malignant tumours |
| 07/12/2006 | CN1802160A Use of heterocyclic compounds as SCCE inhibitors |
| 07/12/2006 | CN1800412A Chip for quick analysis of anti-tumour traditional Chinese medicine molecule toxicity mechanism and its method |
| 07/12/2006 | CN1800388A Eight human miRNAs |
| 07/12/2006 | CN1800387A Small interfering RNA for suppressing multiple effect growth factor expression and its uses |
| 07/12/2006 | CN1800373A Hybridoma cell strain and its produced human VEGFR-3 resistant monoclonal antibody |
| 07/12/2006 | CN1800238A Aliphatic polyester-polyamino acids copolymer with biological function and its synthesis method |
| 07/12/2006 | CN1800208A Snake venom polypeptide and its preparation method |
| 07/12/2006 | CN1800187A Taspine alkaline preparation method and uses in preparing medicine for treating tumour |